Implantable gestrinone
ApprovedSmall molecule
Implantable gestrinone is one of 38 small molecule programs targeting Endometriosis. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
199 competitors in Endometriosis
#DrugCompanyPhaseTrials
1Orilissa
AbbViePhase 3
Revia
TevaPhase 3
Lupron
EEastern Cooperative Oncology Group
Phase 3
Firmagon
FerringPhase 3
Trental
VValidus Pharmaceuticals
Phase 3
Esketamine Hydrochloride
TThe Second Hospital of Anhui Medical University
Phase 3
Implantable gestrinone
BBio Meds Pharmaceutica Ltda
Approved
Add-Back
KKissei Pharmaceutical Co., Ltd.
Phase 3
Visanne
BayerPhase 3
Triptorelin Acetate PR 1-Month
IpsenPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Implantable gestrinone. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- BBio Meds Pharmaceutica Ltda